Retatrutide (LY3437943) — Research Overview

Retatrutide, LY3437943, and the “GLP-3” label

Retatrutide is the recognized compound name; LY3437943 is its development identifier. The PubChem reference record also associates it with CAS 2381089-83-2. A compound identifier helps connect publications and material records, but does not establish a particular vial’s purity, formulation, or identity.

“GLP-3,” “GLP3,” and “GLP 3 peptide” are colloquial search labels for the triple-agonist idea. They are technically misleading if interpreted as the name of a third glucagon-like peptide or a “GLP-3 receptor.” The three relevant targets are GLP-1R, GIPR, and GCGR. Retatrutide is one engineered molecule engaging those receptors, not a mixture made by combining three finished medicines.

Use the recognized name in an experimental record and retain the supplier lot alongside it. If a report uses an informal label, confirm which molecular identity the laboratory actually tested. Do not let a familiar abbreviation substitute for the analytical documentation needed to identify the supplied material.

Molecular design and receptor profile

Coskun and colleagues (2022) describe a 39-residue peptide derived from a GIP backbone. It contains non-coded amino acids and a C20 fatty-diacid group linked at lysine 17, supporting albumin binding. Their cellular work established agonism at all three receptors; the assays showed relatively greater GIPR activity, rather than identical activity at every target.

“Agonist” describes receptor activation. It does not mean that all downstream effects are identical across tissues, species, or assay systems. To reproduce a reported experiment, the relevant information includes the receptor species, cell background, receptor expression, readout, exposure conditions, and analysis model. A short three-receptor label cannot replace those methods.

Binding, functional potency, and time are different measurements

A binding experiment asks whether and how strongly a molecule associates with a target under the stated conditions. A functional experiment measures a response, such as second-messenger signaling. A concentration producing half of a measured response is an EC50; it is not automatically a binding-affinity constant. Different receptor expression or signaling amplification can change the measured functional value.

Binding kinetics add a time dimension: association and dissociation describe how quickly complexes form and separate. Neither an EC50 nor a plasma elimination half-life supplies those rate constants. A six-day circulating half-life must therefore not be rewritten as “six days bound to a receptor.” A study reporting equilibrium binding and functional activity can support those specific findings without proving a receptor-residence time.

For a research comparison, preserve each endpoint’s label and units. Compare like with like, and consult the original methods before combining values across papers. This prevents a potency figure from being mistaken for a clinical dose, or a pharmacokinetic interval from being mistaken for an assay incubation time.

How the target profile differs from Tirzepatide and Semaglutide

The SURPASS-2 trial publication identifies Tirzepatide as a dual GIP/GLP-1 agonist and Semaglutide as a selective GLP-1 agonist. The table is a classification comparison, not a head-to-head efficacy ranking of all three compounds. Separate trials can differ in participants, comparators, duration, estimands, and missing-data handling.

For the site’s broader comparison, see Retatrutide versus Tirzepatide and Semaglutide. Treat the legacy comparison URL as a navigation label; it does not establish that Tirzepatide is the hormone GLP-2 or that Retatrutide is a hormone called GLP-3.

What preclinical and phase 2 studies actually establish

The discovery program combined cell experiments, obese-mouse studies, and an initial human study. In the mouse experiments, the authors attributed part of the response to increased energy expenditure associated with glucagon-receptor activation. That is preclinical mechanistic evidence, not a measured benefit of a research-store product in people. Read the discovery study.

The 2023 phase 2 obesity trial enrolled 338 adults and compared Retatrutide with placebo over 48 weeks. The reported mean weight change in the 12 mg trial group was −24.2%, versus −2.1% with placebo. Gastrointestinal adverse events were common, and heart-rate increases were reported. These figures describe the studied investigational product and trial population; they are not a treatment promise or instructions for using laboratory material. Jastreboff et al. (2023).

A separate phase 2 study evaluated Retatrutide in people with type 2 diabetes, with placebo and an active comparator. It investigated glycemic and bodyweight outcomes in that defined population. Keep it separate from the obesity trial when discussing study design and endpoints. Rosenstock et al. (2023).

These publications are useful for understanding the development program, but they do not establish interchangeability between clinical study material and an independently supplied research vial. Review the intervention, manufacturing context, eligibility criteria, endpoint, follow-up, and sponsor disclosures before extending a result beyond the experiment that produced it.

Half-life and concentration-time curves

The phase 1b study reported an approximately six-day half-life and dose-proportional pharmacokinetics over the investigated range. The study enrolled 72 participants with type 2 diabetes and evaluated multiple weekly study doses over 12 weeks. This is a population-level clinical observation. Urva et al. (2022).

An elimination curve concerns the change in measured circulating concentration over time. Absorption, distribution, and the sampled interval matter when interpreting its shape. The terminal decline is not necessarily the same as the early period after exposure, and a single average value cannot predict a particular person’s concentration or response.

The dedicated Retatrutide half-life guide explains the six-day estimate and a clearly labeled exponential-decay illustration. It also distinguishes elimination from receptor binding, detection windows, and the storage life of laboratory material. Those are separate questions requiring separate evidence.

Stability and handling depend on the supplied material

Circulating half-life does not answer how long a vial remains within specification. Dry material, a prepared solution, and a clinical formulation are different systems. Sequence, excipients, solvent, pH, container, light exposure, temperature history, and the method used to define acceptable quality can all be relevant to a stability assessment. Do not assign a universal shelf life by copying a pharmacokinetic number.

Use the active lot’s instructions and a validated laboratory procedure. Record the received formulation, report revision, storage location, preparation conditions where applicable, and any departure from the intended handling conditions. If the supplied documentation does not support a time or temperature limit, request the relevant evidence rather than treating a generic online range as a measured result.

The storage and laboratory-handling guide and COA guide describe the documentation questions. No specific refrigerator lifetime, freeze-thaw allowance, or post-preparation expiry is assigned by this overview.

Connect the literature to an analytical material record

For laboratory work, keep three records connected: the study or method being investigated, the supplier lot and formulation, and the laboratory’s own preparation and analytical results. The literature describes the molecule and its research context. The supplier documents the offered material. Your local record documents what was actually received and used. None automatically fills a missing field in the others.

Review published batch reports, compare procurement requirements in the Retatrutide sourcing guide, and check Retatrutide research-vial specifications for the current offering. Research materials are not for human or veterinary use, clinical trials, or therapeutic administration.

Development status is time-sensitive. As reviewed September 21, 2026, Lilly still identifies Retatrutide as investigational and not FDA-approved. The phase 2 discussion above is historical evidence, not a claim that phase 2 is the current stage of the entire program.

Frequently asked questions

View Retatrutide specifications and the linked lot reports.

Sources and further reading

• Coskun et al. (2022): discovery and preclinical research
• Urva et al. (2022): phase 1b pharmacokinetics
• Jastreboff et al. (2023): phase 2 obesity trial
• Rosenstock et al. (2023): phase 2 diabetes trial
• Frías et al. (2021): Tirzepatide and Semaglutide trial
• PubChem: Retatrutide identifiers
• Lilly: development status